[HTML][HTML] Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
EH Lips, L Mulder, A Oonk, LE Van Der Kolk… - British journal of …, 2013 - nature.com
EH Lips, L Mulder, A Oonk, LE Van Der Kolk, FBL Hogervorst, ALT Imholz, J Wesseling…
British journal of cancer, 2013•nature.comBackground: BRCAness is defined as shared tumour characteristics between sporadic and
BRCA-mutated cancers. However, how to exactly measure BRCAness and its frequency in
breast cancer is not known. Assays to establish BRCAness would be extremely valuable for
the clinical management of these tumours. We assessed BRCAness characteristics
frequencies in a large cohort of triple-negative breast cancers (TNBCs). Methods: As a
measure of BRCAness, we determined a specific BRCA1-like pattern by array Comparative …
BRCA-mutated cancers. However, how to exactly measure BRCAness and its frequency in
breast cancer is not known. Assays to establish BRCAness would be extremely valuable for
the clinical management of these tumours. We assessed BRCAness characteristics
frequencies in a large cohort of triple-negative breast cancers (TNBCs). Methods: As a
measure of BRCAness, we determined a specific BRCA1-like pattern by array Comparative …
Abstract
Background:
BRCAness is defined as shared tumour characteristics between sporadic and BRCA-mutated cancers. However, how to exactly measure BRCAness and its frequency in breast cancer is not known. Assays to establish BRCAness would be extremely valuable for the clinical management of these tumours. We assessed BRCAness characteristics frequencies in a large cohort of triple-negative breast cancers (TNBCs).
Methods:
As a measure of BRCAness, we determined a specific BRCA1-like pattern by array Comparative Genomic Hybridisation (aCGH), and BRCA1 promoter methylation in 377 TNBCs, obtained from 3 different patient cohorts. Clinicopathological data were available for all tumours, BRCA1-germline mutation status and chemotherapy response data were available for a subset.
Results:
Of the tumours, 66–69% had a BRCA1-like aCGH profile and 27–37% showed BRCA1 promoter methylation. BRCA1-germline mutations and BRCA1 promoter methylation were mutually exclusive events (P= 1× 10− 5). BRCAness was associated with younger age and grade 3 tumours. Chemotherapy response was significantly higher in BRCA1-mutated tumours, but not in tumours with BRCAness (63%(12 out of 19) vs 35%(18 out of 52) pathological complete remission rate, respectively).
Conclusion:
The majority of the TNBCs show BRCAness, and those tumours share clinicopathological characteristics with BRCA1-mutated tumours. A better characterisation of TNBC and the presence of BRCAness could have consequences for both hereditary breast cancer screening and the treatment of these tumours.
nature.com